{"article":{"annotation":{"article_id":"ema-prac-october-2026-pharmacovigilance-outcomes","available_at":"2026-10-12T09:41:45.342573Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"360f1a7e38b1ffd63f964c457f1b37aad76751aca0826ffe31110b3e43e9287b","input_sha256":"67fe6f7519bf041750c9f6477bf1f919fdadb2040ea2111e73f5a89945120c52","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:07000000","confidence":null,"confidence_method":null,"evidence":[{"field":"category+topics","language":"en","note":"Preserved editorial category/topic; broad candidate only","source_urls":["https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october","https://www.ema.europa.eu/no/committees/pharmacovigilance-risk-assessment-committee-prac"]}],"method":"controlled-rules-v1","rule_id":"health-broad","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=en","category":"health","content":{"key_points":[],"paragraphs":["The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) published October figures after its 28 September–1 October meeting. Its monthly summary lists 85 single assessments of periodic safety update reports, 49 risk-management plans for centrally authorised medicines and 16 post-authorisation safety studies.","The committee reported nine safety signals: five were started and four were ongoing or concluded. EMA said the committee did not start or conclude any referral procedure at the meeting. These counts do not establish that a medicine caused harm or that a new restriction was imposed.","The agency says the monthly figures are based on the draft agenda. It defines a safety signal as information that may suggest a medicine-event association requiring further investigation; a signal alone is not proof of causation."],"sections":[]},"corrections":[{"at":"2026-10-07T00:56:16+03:00","language":"en","text":"German and Portuguese editions and translations of the data and correction explanations have been added to this article."},{"at":"2026-10-12T06:19:32+03:00","language":"en","text":"Wording in the translations of data labels or explanations was corrected."}],"country":null,"data":{"blocks":[{"description":{"ar":"أعداد التقييمات الشهرية استناداً إلى جدول الأعمال الأولي.","de":"Monatliche Bewertungszahlen auf Grundlage des Entwurfs der Tagesordnung.","en":"Monthly assessment counts based on the draft agenda.","es":"Recuentos mensuales de evaluaciones según el proyecto de orden del día.","fr":"Nombre mensuel d’évaluations selon le projet d’ordre du jour.","pt":"Contagens mensais de avaliações com base na pauta preliminar.","tr":"Taslak gündeme dayalı aylık değerlendirme sayıları."},"id":"verified-indicators","items":[{"basis":"observed","label":{"ar":"إشارات السلامة","de":"Sicherheitssignale","en":"Safety signals","es":"Señales de seguridad","fr":"Signaux de sécurité","pt":"Sinais de segurança","tr":"Güvenlik sinyalleri"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-safety-signals","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":9},{"basis":"observed","label":{"ar":"التقييمات المنفردة لتقارير PSUR","de":"Einzelbewertungen von PSUR","en":"PSUR single assessments","es":"Evaluaciones únicas de PSUR","fr":"Évaluations uniques de PSUR","pt":"Avaliações individuais de PSUR","tr":"PSUR tekil değerlendirmeleri"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-psur-single-assessments","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":85},{"basis":"observed","label":{"ar":"خطط إدارة مخاطر الأدوية المرخصة مركزياً","de":"Risikomanagementpläne für zentral zugelassene Arzneimittel","en":"Risk-management plans for centrally authorised medicines","es":"Planes de gestión de riesgos para medicamentos autorizados mediante procedimiento centralizado","fr":"Plans de gestion des risques pour les médicaments autorisés par procédure centralisée","pt":"Planos de gerenciamento de riscos para medicamentos autorizados por procedimento centralizado","tr":"Merkezi ruhsatlı ilaçlar için risk yönetim planları"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-central-risk-plans","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":49},{"basis":"observed","label":{"ar":"دراسات السلامة بعد الترخيص","de":"Sicherheitsstudien nach der Zulassung","en":"Post-authorisation safety studies","es":"Estudios de seguridad posteriores a la autorización","fr":"Études de sécurité post-autorisation","pt":"Estudos de segurança pós-autorização","tr":"Ruhsat sonrası güvenlilik çalışmaları"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-post-authorisation-safety-studies","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":16},{"basis":"observed","label":{"ar":"إجراءات الإحالة التي بدأت أو استمرت أو اختُتمت","de":"Begonnene, laufende oder abgeschlossene Befassungsverfahren","en":"Referrals started, ongoing or concluded","es":"Remisiones iniciadas, en curso o concluidas","fr":"Saisines commencées, en cours ou conclues","pt":"Procedimentos de encaminhamento iniciados, em andamento ou concluídos","tr":"Başlatılan, süren veya sonuçlanan sevk prosedürleri"},"measure":{"aggregation":"flow","frequency":"monthly","geography":"european-union","id":"prac-referral-procedures","periodRole":"announcement-date","unitCode":"count"},"period":"2026-10","unit":"count","value":0}],"methodology":{"ar":"إشارة السلامة ليست دليلاً على السببية؛ وجميع الأعداد مبنية على جدول الأعمال الأولي.","de":"Ein Sicherheitssignal beweist keine Ursache; alle Zahlen beruhen auf dem Entwurf der Tagesordnung.","en":"A safety signal is not proof of causation; all counts are based on the draft agenda.","es":"Una señal de seguridad no prueba causalidad; todos los recuentos se basan en el proyecto del orden del día.","fr":"Un signal de sécurité ne prouve pas la causalité ; tous les chiffres reposent sur le projet d’ordre du jour.","pt":"Um sinal de segurança não comprova causalidade; todas as contagens se baseiam na pauta preliminar.","tr":"Güvenlik sinyali nedensellik kanıtı değildir; tüm sayılar taslak gündem temellidir."},"sourceUrls":["https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october"],"title":{"ar":"إحصاءات لجنة PRAC في أكتوبر","de":"PRAC-Statistik für Oktober","en":"PRAC October statistics","es":"Estadísticas de octubre del PRAC","fr":"Statistiques d’octobre du PRAC","pt":"Estatísticas do PRAC em outubro","tr":"PRAC ekim istatistikleri"},"type":"metrics","updatedAt":"2026-10-12T06:19:32+03:00"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes/data/verified-indicators?lang=en&format=csv","json":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes/data/verified-indicators?lang=en&format=json"},"id":"verified-indicators"}],"data_types":["metrics"],"editorial_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-4e22bbce-1bd4-5a4f-adf7-eedfd2dca91c","event_period":"2026-10-02","event_period_basis":"event-or-reference-period","id":"ema-prac-october-2026-pharmacovigilance-outcomes","image":null,"importance":0.6,"language":"en","modified_at":"2026-10-12T06:19:32+03:00","publication_basis":"publication-record","published_at":"2026-10-04T01:05:40+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Conceptual illustration of public health, research and connected data.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"caption":null,"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"en","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"ema-prac-october-2026-pharmacovigilance-outcomes","sources":[{"checkedAt":"2026-10-04","name":"European Medicines Agency","publishedAt":"2026-10-02","url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-september-1-october"},{"checkedAt":"2026-10-04","name":"European Medicines Agency PRAC committee calendar","url":"https://www.ema.europa.eu/no/committees/pharmacovigilance-risk-assessment-committee-prac"}],"summary":"PRAC’s monthly figures list nine safety signals, 49 risk-management plans and 16 post-authorisation studies.","text":"PRAC’s monthly figures list nine safety signals, 49 risk-management plans and 16 post-authorisation studies.\n\nThe European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) published October figures after its 28 September–1 October meeting. Its monthly summary lists 85 single assessments of periodic safety update reports, 49 risk-management plans for centrally authorised medicines and 16 post-authorisation safety studies.\n\nThe committee reported nine safety signals: five were started and four were ongoing or concluded. EMA said the committee did not start or conclude any referral procedure at the meeting. These counts do not establish that a medicine caused harm or that a new restriction was imposed.\n\nThe agency says the monthly figures are based on the draft agenda. It defines a safety signal as information that may suggest a medicine-event association requiring further investigation; a signal alone is not proof of causation.\n\nGerman and Portuguese editions and translations of the data and correction explanations have been added to this article.\n\nWording in the translations of data labels or explanations was corrected.","title":"EMA safety committee assessed 85 medicine reports in October","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=en","language":"en","url":"https://newsverum.com/en/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=es","language":"es","url":"https://newsverum.com/es/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=de","language":"de","url":"https://newsverum.com/de/news/ema-prac-october-2026-pharmacovigilance-outcomes"},{"api_url":"https://newsverum.com/api/v1/articles/ema-prac-october-2026-pharmacovigilance-outcomes?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/ema-prac-october-2026-pharmacovigilance-outcomes"}],"url":"https://newsverum.com/en/news/ema-prac-october-2026-pharmacovigilance-outcomes"},"version":"1"}
